The new insulin, which is installed with Bluetooth interface, transfers the injected insulin doses directly to the patient’s digital blood glucose diary.
Connected via 868 MHz interface, the smart insulin pens are already being successfully used in medicine in combination with a wireless transmission blood glucose meter as an Esysta integrated diabetes management system.
The patented ESYSTA solution enables doctors to provide better medical care for Type 1 and Type 2 diabetic patients.
Emperra is also seeking the approval from the US Food and Drug Administration (FDA) for the insulin pen based Esysta telemonitoring solution. The device is expected to be approved by the end of this year.
According to the company, Esysta convinced most patients, their doctors and care-givers within the first few months during a medical and health economic field trial by German health insurance companies.
In addition, the mobile CE-compliant Esysta app for iOS and Android provides treatment recommendations for patients.
Emperra CEO Dr Christian Krey said: “The smart insulin pen and corresponding software appeal to patients and doctors who prefer state-of-the-art technical solutions and who have recognised that the digitalisation of diabetes management is a simple and reliable solution.”
Emperra is engaged in the development of concepts and solutions in the fields of e-health technologies and telediabetology.
Image: Esysta web-based telemonitoring system consisting of a base unit, insulin pen, blood glucose meter, app and online portal. Photo: courtesy of Emperra GmbH / B3C Group GmbH.
